Study on the influencing factors of sacubitril/valsartan clearance in peritoneal dialysis

A non-interventional study on the influencing factors of sacubitril/valsartan clearance in peritoneal dialysis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055924

Enrollment

Unknown

Registered

2022-01-25

Start date

2022-02-07

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Interventions

Patients with routine peritoneal dialysis evaluation:NA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have undergone regular continuous ambulatory peritoneal dialysis (CAPD) for more than 3 months in the Department of Nephrology of our hospital and come to the hospital for routine peritoneal dialysis evaluation; 2. Aged 18 to 80 years; 3. Take sacubitril-valsartan regularly for more than 3 days.

Exclusion criteria

Exclusion criteria: 1. Patients with liver function damage, cholestasis, biliary cirrhosis; 2. Patients with peritonitis or other serious systemic infections; 3. There are events that may affect follow-up, such as the existence of malignant tumors, drug or alcohol abuse patients; 4. Patients with severe mental disorders were excluded.

Design outcomes

Primary

Measure	Time frame
plasma-valsartan;plasma-sacubitril;plasma-LBQ657;urine-valsartan;urine-sacubitril;urine-LBQ657;peritoneal dialysis fluid-valsartan;peritoneal dialysis fluid-sacubitril;peritoneal dialysis fluid-LBQ657;	—

Countries

China

Contacts

Public ContactZhong Hui

West China Hospital of Sichuan University

medzhonghui@163.com+86 18980601215

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 30, 2026